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ABSTRACT
Human embryonic stem cells (hESCs) and human induced pluripotent stem cells (hiPSCs) are
defined as pluripotent in view of their self-renewal ability and potential to differentiate to cells of
all three germ layers. Recent studies have indicated that microRNAs (miRNAs) play an important
role in the maintenance of pluripotency and cell cycle regulation. We used a microarray based
approach to identify miRNAs that were enriched in hESCs when compared to differentiated cells
and at the same time showed significant expression changes between different phases of cell
cycle. We identified 34 candidate miRNAs and performed functional studies on one of these, miR-
1305, which showed the highest expression change during cell cycle transition. Overexpression of
miR-1305 induced differentiation of pluripotent stem cells, increased cell apoptosis and sped up
G1/S transition, while its downregulation facilitated the maintenance of pluripotency and
increased cell survival. Using target prediction software and luciferase based reporter assays we
identified POLR3G as a downstream target by which miR-1305 regulates the fine balance between
maintenance of pluripotency and onset of differentiation. Overexpression of POLR3G rescued plu-
ripotent stem cell differentiation induced by miR-1305 overexpression. In contrast, knock-down of
POLR3G expression abolished the miR-1305-knockdown mediated enhancement of pluripotency,
thus validating its role as miR-1305 target in human pluripotent stem cells. Together our data
point to an important role for miR-1305 as a novel regulator of pluripotency, cell survival and cell
cycle and uncovers new mechanisms and networks by which these processes are intertwined in
human pluripotent stem cells. STEM CELLS 2016; 00:000–000
SIGNIFICANCE STATEMENT
Pluripotent stem cells hold great promise for basic biology studies, understanding of human
development and for cell based replacement therapies of inherited and age related degenera-
tive diseases. However, to fully realise their potential and to avoid safety concerns, directed,
and efficient strategies must be developed to control their differentiation along desired line-
ages. This requires a fundamental understanding of the molecular mechanisms underlying self-
renewal and maintenance of pluripotency. Along with signalling pathways, transcription factors,
and epigenetic regulators, miRNAs are emerging as important regulators in the maintenance of
pluripotency and the cell cycle. In this present study, we have identified a novel regulator of
pluripotency, cell survival and cell cycle, namely miR-1305 and have provided evidence that
miR-1305 regulates the pluripotency-differentiation balance by directly binding to the 30UTR of
POLR3G pluripotency factor and regulating its expression.
INTRODUCTION
Human pluripotent stem cells have two unique
properties: unlimited self-renewal and pluripo-
tency [1, 2]. MicroRNAs (miRNAs) are a class
of small (18–25 nucleotides) regulatory non-
coding RNAs that are thought to regulate gene
expression through sequence-specific base
pairing with target mRNAs [3]. Recent studies
have highlighted an important role for miRNAs
in maintaining the delicate balance between
pluripotency and the onset of differentiation
through close links with the pluripotency tran-
scription network. Key pluripotency factors
(Sox2, Oct4, and Nanog) can regulate the
expression of pluripotent stem cell (ESC) spe-
cific miRNAs (for example mir-290 and 302
clusters) by binding to their promoters [4, 5].
In turn, miRNAs (for example miR-134, miR-
296, and miR-470) can target the coding
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sequence of Sox2, Oct4, and Nanog in various combinations
leading to the loss of pluripotency and onset of differentiation
[6, 7]. Furthermore, miRNAs (mir-302, 367, 145, etc) have
been implicated in somatic cell induced reprogramming
through regulating the expression of master pluripotency fac-
tors, epigenetic factors and genes involved in mesenchymal to
epithelial transition [8, 9].
Rapid cell cycle progression is a distinct feature of pluripo-
tent stem cells. A short G1 phase has been considered impor-
tant for the maintenance of pluripotency by limiting the
window of opportunity during which pluripotent stem cells
are exposed to differentiation cues [10–12]. Recent evidence
suggests that miRNAs regulate many genes that are involved
in cell cycle progression in ESCs [13]. Depletion of miRNAs
through knockdown of Dicer and Drosha in murine ESC results
in slower proliferation and accumulation of cells in G1 phase
of the cell cycle [14, 15] which can be rescued by overexpres-
sion of the mir-290/302 cluster [16] and early differentiation
factors (Wee1 and Fbx15) [16, 17].
Knockdown of DICER or DROSHA in human ESCs (hESCs)
also results in reduced generation of miRNAs and accumula-
tion of cells in the G1 and G2/M phases of cell cycle [18]. The
G1 blockage can be rescued by overexpression of miR-372
which has been shown to regulate the cyclin E/Cdk2 pathway
in G1/S transition by inhibiting the cell cycle inhibitor CDKN1A
(p21) [18]. The G2/M cell accumulation can be reversed by
the overexpression of miR-195 which regulates WEE1 kinase,
a known inhibitor of cyclin B/Cdk1 which is necessary for G2/
M transition [18]. Moreover, the miR-302 cluster, which is the
most enriched miRNA cluster in hESCs and important for the
maintenance of pluripotency also promotes G1/S transition by
inhibiting cyclin D1. In support of this role, it has been shown
that inhibition of miR-302 induces cell accumulation in G1
phase and the onset of differentiation [5, 19]. Together these
published data indicate that ESCs specific miRNAs have a cen-
tral role in expediting the G1-S transition and promoting cellu-
lar proliferation.
In this present study, we have identified a novel regulator
of early differentiation events, cell survival and cell cycle,
namely miR-1305 and have provided evidence that miR-1305
regulates the pluripotency-differentiation balance by directly
binding to the 30UTR of POLR3G pluripotency factor and regu-
lating its expression.
RESULTS
Microarray-Based Expression Profiling at Different
Stages of the hESCs Cell Cycle and Differentiation
Process
Our previous studies have shown that cell cycle regulation
and pluripotency are two critically intertwined processes that
may be regulated by key pluripotency factors including miR-
NAs [20, 21] . To identify miRNA candidates which are likely
to regulate the pluripotent phenotype as well as the cell
cycle, we synchronised hESCs at different cell cycle stages
(G1, S, and G2/M; Supporting Information Fig. 1A). RNAs
obtained from these samples as well as human placental
fibroblasts and unsynchronised hESCs were used for miRNA
screening analysis using the Agilent human miRNA (V3) 8X15K
microarray (Agilent, G4470) containing 866 human and 89
human viral miRNAs probes.
The expression data generated from the array were nor-
malized using the quintile normalization method [22] and dif-
ferential miRNA expression method using the Limma package
from Bioconductor [23]. Statistical probability of significance
(adjusted p values, set at p <.05) and a fold-change >2.0
were used to select the miRNAs that were differentially
expressed between hESCs and human placental fibroblasts
and those with significant expression changes between differ-
ent stages of the hESCs cycle (Fig. 1A). A Venn diagram analy-
sis was carried out (Fig 1B) and 34 miRNAs were identified in
the central shared area (Supporting Information Table 1).
Recent studies have shown that the S and G2 phase of plurip-
otent stem cell cycle possess intrinsic properties toward the
pluripotent state that are independent of G1 phase [24]. For
this reason, we focused our attention on one particular candi-
date, miR-1305, which showed the highest expression in S
phase of the cell cycle (Fig. 1C) alongside higher expression in
hESCs when compared to human placental fibroblasts (Sup-
porting Information Table 1), which suggest that this candi-
date may have important functions in regulating both cell
cycle and hESCs differentiation.
To confirm the array expression studies we performed
qRT-PCR analysis. miR-367, a well-known miRNA that controls
self-renewal and pluripotency in hESCs and human induced
pluripotent stem cells (hiPSCs), was used as a positive control
[19]. This indicated that the highest expression of miR-1305
was observed during S phase of the cell cycle (Fig. 1C). Fur-
thermore, qRT–PCR was used to test miR-1305 expression
during hESCs differentiation. Embryoid bodies (EB) were
formed from hESCs and miR-1305 expression analysed at time
points throughout differentiation. Our results indicated that
expression of miR-1305 was upregulated at day 1 of hESCs
differentiation followed by a significant downregulation from
day 3 onward (Fig. 1D), thus corroborating the reduced
expression in differentiated cells as shown from the array
analysis. miR-367 was highly expressed in G1 phase of the cell
cycle (Supporting Information Fig. 1B) as well as significantly
downregulated during hESCs differentiation (Supporting Infor-
mation Fig. 1C) in agreement with previously published
results [19].
The Role of miR-1305 in Regulating Pluripotency
To further investigate the function of miR-1305 in hESCs, we
overexpressed miR-1305 using a miR-1305 overexpression
mimic (Thermo Fisher). Quantitative RT-PCR analysis at differ-
ent time intervals (24–96 hours) indicated that miR-1305
expression peaked at 24 hours post-transfection (>1000 fold)
when compared to hESCs transfected with a scrambled
miRNA overexpression control (Fig. 2A). We observed that
cells transfected with the miRNA overexpression control main-
tained a typical hESCs morphology. At the same time, colonies
in the miR-1305 overexpression group were noticeably smaller
and containing cells which had begun to lose the undifferenti-
ated hESCs morphology, indicative of the onset of differentia-
tion (Fig. 2B). Quantitative RT-PCR analysis indicated a small
but significant downregulation of the pluripotency markers
OCT4 and NANOG (Fig. 2C) and increased expression of primi-
tive ectoderm (FGF5), neuroectoderm (PAX6), mesoderm (T),
endoderm markers (GATA4 and FOXA1), and trophectoderm
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markers (CDX2 and HAND1; Fig. 2D). It is interesting to note
that unlike other germ-layer markers, the expression of
FOXA2, a definitive endoderm marker, was downregulated
upon miR-1305 overexpression (Fig. 2D). Flow cytometric
analysis also indicated an increase in the percentage of cells
expressing the early differentiation marker, SSEA-1 (Fig. 2E). In
summary, the results from this analysis coupled with the early
upregulation of miR-1305 expression (from day 0 to day 1)
suggest that miR-1305 overexpression induces the early hESCs
differentiation.
Figure 1. Identification of candidate miRNAs involved in maintenance of pluripotency and cell cycle regulation in pluripotent stem
cells. (A): Summary table displaying the number of candidate miRNA whose expression changed significantly (p< .05 and fold change-
> 2.0) during cell cycle stages or between hESCs and human placental fibroblasts; (B): Venn diagram representation of candidate miR-
NAs shown in (A) and selection of 34 candidate miRNAs that were differently expressed between hESCs versus human placental
fibroblast cells, S phase versus G1 phase, and S phase versus G2 phase; (C): Quantitative RT-PCR analysis of miR-1305 expression in vari-
ous cell cycle stages in hESC. Data is presented as mean6 SEM (n5 3). The unsynchronised control was set to 1.0 and all other values
were calculated with respect to that. Significance was assessed using Student t-test, ** p <.01; (D): Quantitative RT-PCR analysis of
miR-1305 expression during hESC differentiation using the Embryoid body method (EB). Ad3 fibroblasts – dermal skin fibroblasts from a
37-year-old Adult. Data is presented as mean6 SEM (n5 3). The H9 was set to 1.0 and all other values were calculated with respect to
that. Significance was assessed using Student t-test, ** p< .01.
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To further understand the function of miR-1305 in pluripo-
tency, we performed loss of function studies by using miRNA-
inhibitors (Thermo Fisher). Quantitative RT-PCR analysis indi-
cated that the miR-1305 inhibition significantly reduced miR-
1305 levels from 24–96 hours post transfection when com-
pared to hESCs transfected with a scrambled miRNA control
(Fig. 3A). Morphological assessment indicated that hESCs
transfected with the control inhibitor or the miR-1305 inhibi-
tor, maintained their typical undifferentiated hESCs morpholo-
gy (Fig. 3B), indicating that miR-1305 inhibition did not induce
hESCs differentiation. Furthermore, the colonies in the miR-
1305 inhibition group generally appeared to be bigger than in
the control group and were devoid of the differentiated cells
often observed at the edge of hESCs colonies (Fig. 3B). Quan-
titative RT-PCR analysis indicated a slight but significant
increase (10–20%) in the expression of the pluripotency
markers OCT4 and NANOG (Fig. 3C) and a reduction in the
expression of primitive ectoderm (FGF5), mesoderm (T and
MIXL1), endoderm (GATA4 and FOXA1), and trophectoderm
(HAND1) markers (Fig. 3D). It is interesting to note again, that
unlike any other germ layer makers tested, the expression of
FOXA2, a definitive endoderm marker, was significantly upre-
gulated (2.5-folds) upon miR-1305 inhibition (Fig. 3D). These
data suggest that miR-1305 expression is likely to enhance
the maintenance of hESCs pluripotency.
To investigate the role of miR-1305 in hiPSC, we per-
formed miRNA overexpression and inhibition transfection
experiments in hiPSCs (Ad3 clone 1) generated from adult
dermal skin fibroblasts and well characterised by our group.
Quantitative RT-PCR analysis indicated similar results to those
Figure 2. miR-1305 overexpression induces hESCs differentiation. (A): Quantitative RT-PCR analysis of miR-1305 expression after control
miRNA overexpression or miR-1305 overexpression (OE). Data is presented as mean6 SEM (n5 3). The miRNA overexpression control
was set to 1.0 and all other values were calculated with respect to that. Significance was assessed using Student t-test, *p <.05, **p
<.01; (B): Phase contrast observation of hESCs morphology at 24 and 48 hours post transfection with either control miRNA or miR-1305
overexpression. Scale bars, 200 mm. This is a representative example of at least three independent experiments; (C): Quantitative RT-
PCR analysis of the expression levels of pluripotency markers OCT4 and NANOG in hESCs at 48 hours after transfection with control
miRNA or miR-1305 overexpression (OE). Data is presented as mean6 SEM (n5 3). The miRNA overexpression control was set to 1.0
and all other values were calculated with respect to that. Significance was assessed using Student t-test, *p< .05, **p< .01; (D): Quan-
titative RT-PCR analysis of the expression levels of differentiation markers in hESCs at 48 hours after transfection with a miRNA overex-
pression control or miR-1305 overexpression (OE). Data is presented as mean6 SEM (n5 3). The miRNA overexpression control was set
to 1.0 and all other values were calculated with respect to that. Significance was assessed using Student t-test, *p <.05, **p <.01; (E):
Flow cytometric analysis showing percentage of SSEA1 positive cells after overexpression of miR-1305 at 48 hours after transfection.
Data is presented as mean6 SEM (n5 3). Significance was assessed using Student t-test, **p< .01.
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from the hESC experiments: miR-1305 overexpression reduced
the expression of pluripotency markers OCT4 and NANOG
(data not shown) and increased the expression of ectoderm
(FGF5 and PAX6), mesoderm (T), endoderm (GATA4 and
FOXA1), and trophectoderm (CDX2 and HAND1) markers (Sup-
porting Information Fig. 2). When miR-1305 was inhibited, we
could detect an increase in the pluripotency markers OCT4
and NANOG (data not shown) and a reduction in ectoderm
(FGF5 and PAX6), mesoderm (T), endoderm (GATA4 and
FOXA1), and trophectoderm (CDX2 and HAND1) markers (Sup-
porting Information Fig. 2). These results indicate that miR-
1305 functions are similar between hESCs and hiPSCs.
The Role of miR-1305 in Regulating Cell Cycle
and Apoptosis
To test the function of miR-1305 in cell cycle regulation, we
synchronised hESCs at G2/M phase of the cell cycle by incu-
bation with 200 ng/ml of the mitotic inhibitor nocodazole for
18 hours as described in Neganova et al. (2009) [20] and
Zhang et al. (2009) [21]. We assessed the percentage of cells
in each stage of cell cycle by flow cytometric analysis as
shown in Supporting Information Figure 3A. Upon release
from G2/M accumulation, the hESCs cell cycle distribution
was investigated by flow cytometry at regular intervals. This
Figure 3. Knockdown of miR-1305 in hESCs supports the maintenance of pluripotency. (A): Quantitative RT-PCR analysis of miR-1305
expression after miRNA knockdown control or miR-1305 knockdown transfection (KD). Data is presented as mean6 SEM (n5 3). The
miRNA knockdown control was set to 1.0 and all other values were calculated with respect to that. Significance was assessed using Stu-
dent t-test, *p< .05, **p< .01; (B): Phase contrast observation of hESCs morphology at 24 and 48 hours of transfection with miRNA
knockdown control or miR-1305 knockdown (KD). Scale bars, 200 mm. This is a representative example of at least three independent
experiments; (C): Quantitative RT-PCR analysis of the expression levels of pluripotency markers OCT4 and NANOG in hESCs at 48 hours
after transfection with miRNA knockdown control or miR-1305 knockdown (KD). Data is presented as mean6 SEM (n5 3). The miRNA
knockdown control was set to 1.0 and all other values were calculated with respect to that. Significance was assessed using Student t-
test, *p< .05, **p< .01; (D): Quantitative RT-PCR analysis of the expression levels of differentiation markers in hESCs at 48 hours after
transfection with miRNA knockdown control or miR-1305 knockdown (KD). Data is presented as mean6 SEM (n5 3). The miRNA knock-
down control was set to 1.0 and all other values were calculated with respect to that. Significance was assessed using Student t-test,
*p< .05, **p <.01.
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analysis indicated a higher percentage of cells in S phase and
a lower percentage of cells in G1 phase of the cell cycle at 6
and 8 hours post-release from G2/M accumulation when the
miR-1305 overexpressing group was compared to the control;
however no changes were observed through G2 exit or entry
(Supporting Information Fig. 3B). Inhibition of miR-1305
expression resulted in increased cell accumulation in G1 phase
at 10 hour time point. Furthermore a slightly higher percent-
age of cells was observed at G2 at this time point suggestive
of a faster S to G2/M exit (Supporting Information Fig. 3C).
The slower entry into S and faster exit from S to G2/M
resulted in lower percentage of cells observed at S phase at
this time point. Together these data suggest that overexpres-
sion of miR-1305 speeds up the G1 to S transition, whilst its
downregulation appears to slow down G1 to S transition and
to slightly speed up the S to G2/M transition.
We noticed that overexpression of miR-1305 results in for-
mation of smaller hESCs colonies and presence of apoptotic
cells in the culture media. This led us to investigate the
impact of miR-1305 overexpression and inhibition on pluripo-
tent stem cell survival. Flow cytometric assays (Annexin V/PI
and PARP activation) at 48 hours post transfection showed a
higher percentage of apoptotic cells in the miR-1305 overex-
pressing group compared to control (Supporting Information
Fig. 4A). The opposite was observed upon downregulation of
miR-1305 (Supporting Information Fig. 4B). Together these
data indicate that miR-1305 plays an important role in cell
cycle regulation and survival in pluripotent stem cells.
Identification of POLR3G As a Direct Target
of miRNA-1305
To find potential miR-1305 targets, we used several well-
known prediction softwares (TargetScan, miRDB, TargetMINER,
RNA22-HAS, and microRNA). To narrow down the candidate
miR-1305 targets, we focused on genes with known functions
in the maintenance of pluripotency, cell cycle regulation or
differentiation that were also predicted by more than one of
the above mentioned softwares (Supporting Information Table
2). By comparing the software prediction results, three poten-
tial targets (LIN28A, POLR3G, and ZIC2) which have previously
been implicated in maintenance of pluripotency in hESCs
were chosen for further study (Supporting Information Table
3). LIN28A regulates the balance between stem cell differenti-
ation and maintenance of pluripotency through targeting let-7
[25]. POLR3G, a downstream target of OCT4 and NANOG, is a
novel pluripotency regulator in hESCs and is controlled by the
ERK1/2 signalling pathway [26]. ZIC2 is a member of the ZIC
family which is a negative regulator of Wnt signalling thought
to be responsible for the formation of the brain signalling
centre located at the midbrain-hindbrain boundary in frog
embryos [27].
To confirm whether these three genes were bona fide tar-
gets, we performed quantitative RT-PCR and Western Blot
analysis. We characterized the mRNA expression levels of
these predicted target genes in miR-1305-overexpressed and/
or inhibited pluripotent stem cells using qRT-PCR. Whilst the
qRT-PCR analysis showed the expected pattern of gene down-
regulation upon miR-1305 overexpression and gene upregula-
tion upon miR-1305 inhibition (Fig. 4A and 4B), the Western
Blot analysis confirmed this pattern only for POLR3G (Fig. 4C
and 4D). From these data, we concluded that POLR3G is likely
to be a direct downstream miR-1305 target.
To confirm the direct regulation between miR-1305 and
POLR3G, we performed binding site predication for POLR3G.
Three putative miR-1305 binding sites were identified in the
30UTR of POLR3G gene (Fig. 4E), all of which were conserved
between different species (Supporting Information Table 3A).
We investigated the functional interaction between miR-1305
and the POLR3G 30-UTR by cloning the POLR3G 30-UTR into
the psiCHECKTM-2 vector (Promega) in order to create a
reporter assay. This was used to investigate the binding specif-
icity of miR-1305 to POLR3G by mutating all three binding
sites separately or together (Supporting Information Table
3B). The reporter assay indicated that the ectopic expression
of miR-1305 significantly suppressed (45%) the activity of
the POLR3G reporter (Fig. 4E). Moreover, this inhibitory effect
could be significantly abolished when binding site 1 (mu-1), 2
(mu-2) and all three sites (mu-all) were mutated (Fig. 4E).
Together, these data shows that miR-1305 regulates POLR3G
expression by binding to its 30UTR.
miR-1305 Regulates the pluripotency-Differentiation
Balance through POLR3G
To test whether miR-1305 regulates the balance between
maintenance of pluripotency and onset of differentiation in
pluripotent stem cells by targeting POLR3G, we utilised over-
expression and knockdown of both POLR3G and miR-1305 in
hESCs. To test whether POLR3G overexpression could inhibit
hESCs differentiation induced by miR-1305 overexpression we
generated a POLR3G-overexpressing stable cell line. The cod-
ing region of POLR3G was cloned into a vector with a CAG-
promoter and a puromycin expression cassette and trans-
fected into hESCs followed by puromycin selection (1.0 lg/
ml). Both the mRNA (twofold higher) and the protein levels
of POLR3G were increased in the stable cell line compared to
the control (Supporting Information Fig. 5A and 5B). The
POLR3G-CAG line alongside an empty-CAG control line was
subjected to miR-1305 overexpression in the following experi-
mental groups: (1) miRNA overexpression control/control-CAG,
(2) miR-1305 overexpression/control-CAG, and (3) miRNA-
1305 overexpression/POLR3G overexpression. The relative lev-
els of differentiated lineage markers were assessed by qRT-
PCR. As expected, miR-1305 overexpression increased the lev-
els of trophectoderm (CDX2 and HAND1), primitive ectoderm
(FGF5), neuroectoderm (PAX6), mesoderm (T), and endoderm
(GATA4 and FOXA1) markers (Fig. 5A). POLR3G overexpression
abolished the increase of all these differentiation markers,
indicating that miR-1305 overexpression induced differentia-
tion by regulating POLR3G.
To further confirm that miR-1305 regulate hESC differen-
tiation by targeting POLR3G, we utilised knockdown of
POLR3G and inhibition of miR-1305 in hESCs. The efficiency
of knockdown was tested by qRT-PCR. POLR3G siRNA alone
reduced POLR3G expression by 70% and miRNA/siRNA co-
inhibition reduced the POLR3G expression by 50% (Support-
ing Information Fig. 5C). The experiment was set up as three
groups: (1) miRNA knockdown control/control siRNA; (2)
miR-1305 knockdown/control siRNA; (3) miR-1305 knock-
down/POLR3G siRNA and expression of markers of differenti-
ation studied by qRT-PCR. As expected, miR-1305 inhibition
significantly reduces (10–40%) the expression of all the
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Figure 4. POLR3G is the downstream target of miR-1305 in hESCs. (A): Quantitative RT-PCR analysis of the expression levels of the pre-
dicted miR-1305 targets after miR-1305 overexpression (OE). Data is presented as mean6 SEM (n5 3). The miRNA overexpression con-
trol was set to 1.0. Significance was assessed using Student t-test, **p< .01; (B): Quantitative RT-PCR analysis of the expression levels
of the predicted miR-1305 targets after miR-1305 knockdown (KD). Data is presented as mean6 SEM (n5 3). The miRNA knockdown
control was set to 1.0 and all other values were calculated with respect to that. Significance was assessed using Student t-test, *p< .05,
**p< .01; (C): Western blot analysis of the protein levels of POLR3G, ZIC2 and LIN28A. GAPDH served as a loading control. One repre-
sentative example from three independent biological replicates is shown; (D): Quantification of POLR3G, LIN28A and ZIC2 protein. The
protein expression value of miRNA OE control or miRNA KD control was set as 1 and all the other values were calculated with respect
to that. Data is presented as mean6 SEM (n5 3). Significance was assessed using Student t-test, *p< .05, **p< .01. (E): Dual luciferase
reporter assays in hESCs co-transfected with dual-luciferase constructs containing wild-type (wt-POLR3G) or the POLR3G 30-UTR mutants
(mu 1-3 and mu-All) together with the miRNA overexpression control or miR-1305 overexpression mimic. The ratio between Renilla and
Firefly luciferase activity was calculated. Then the ratio between transfections done on presence of miR-1305 overexpression to miR
overexpression control was calculated for each transfection resulting in luciferase activity value. The luciferase activity value of cells
transfected with the empty luciferase vector was set as 1.0 and all the other values were calculated with respect to that. Data is pre-
sented as mean6 SEM (n5 3). Significance was assessed using Student t-test, *p< .05, **p< .01, N.S.: not significant. Mu-All includes
mutations for all three identified miR-1305 binding sites.
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differentiation markers, while this effect is abolished in the
miR-1305 inhibition and POLR3G knockdown scenario where
all the differentiation makers are upregulated compared to
miR-1305 inhibition alone (Fig. 5B). Together these data pro-
vide strong evidence that miR-1305 impacts on the mainte-
nance of hESCs pluripotency and the onset of their
differentiation via binding directly to the 30UTR of POLR3G
and regulating its expression.
DISCUSSION
Pluripotent stem cells hold great promise for basic biology
studies, understanding of human development and as thera-
peutic options in cell based replacement therapies of inher-
ited and age related degenerative diseases [28–30]. However,
to fully realise their potential and to avoid safety issues,
directed and efficient strategies must be developed to control
their differentiation along desired lineages. This requires a
fundamental understanding of the molecular mechanisms
underlying self-renewal and maintenance of pluripotency.
Along with signalling pathways, transcription factors and epi-
genetic regulators, miRNAs are emerging as important regula-
tors in the maintenance of pluripotency and the cell cycle
[16, 31]. The interplay between cell cycle regulation and con-
trol of pluripotent stem cell differentiation represents a major
interest for the stem cell field since differentiation to specific
lineages has been shown to be highly dependent on the cell
cycle stage. For example, hESCs in early G1 phase can only
initiate differentiation into endoderm, whereas hESCs in late
G1 are limited to neuroectoderm differentiation [10]. In accor-
dance with these published data, our group and others have
shown that pluripotent stem cells residing in S and G2 are
more effective at maintaining stemness [24, 32]. Bearing this
in mind, we set out to identify candidate miRNAs important
for maintenance of pluripotency using two selection criteria:
(1) significantly higher expression in S phase when compared
to G1 and G2 phase of the cell cycle and (2) significantly
higher expression in pluripotent stem cells when compared to
somatic cells.
We focused our attention on a novel miRNA, miR-1305
and performed further functional studies to elucidate for the
first time its role in pluripotent stem cells. These showed that
expression of miR-1305 is upregulated very rapidly upon the
onset of differentiation (within 24 hours), indicating a role in
early differentiation. Furthermore, miR-1035 downregulation
contributed to consolidation of pluripotent phenotype and its
overexpression led to initiation of differentiation, thus sugges-
ting that miR-1305 acts as a regulator maintaining the fine
balance between pluripotency and differentiation, presumably
by modulating the expression of genes involved in this pro-
cess. Using a combination of target prediction softwares and
luciferase reporter assays, we identified POLR3G as a bona
fide miR-1305 target, thus providing for the first time evi-
dence of a direct link between POLR3G and miR-1305 in regu-
lating hESC pluripotency. POLR3G, a downstream target of
OCT4 and NANOG has been shown to play an important role
in maintaining hESC pluripotency, as decreased levels of
POLR3G result in loss of pluripotency and promote hESCs dif-
ferentiation (Fig. 6), while its overexpression makes hESCs
more resistant to differentiation [26]. Our results fully corrob-
orate these published findings and add another layer of
molecular regulation by providing experimental evidence on
regulation of pluripotency and differentiation through
POLR3G/miR-1305 mediated expression. Previous studies have
shown that POLR3G is present in the cytoplasm of fertilized
mouse zygotes and two-cell embryos, but is located in the
nucleus during the 8-16-cell and the blastocyst stage [26]. Giv-
en our data on possible regulation of this gene by miR-1305
in pluripotent stem cells, it would be of interest to investigate
whether such interactions extend to the window proceeding
Figure 5. miR-1305 regulates hESCs pluripotency-differentiation
balance through POLR3G. (A): Quantitative RT-PCR analysis of the
expression levels of differentiation markers in the control-CAG
cell line or the POLR3G-CAG cell line at the second day after
transfection with a miRNA overexpression control or a miRNA-
1305 overexpression (OE). The miRNA overexpression control was
set to 1.0 and all other values were calculated with respect to
that. Data is presented as mean6 SEM (n5 3). Significance was
assessed using Student t-test, *p< .05, **p< .01; (B): Quantita-
tive RT-PCR analyses of the expression levels of differentiation
markers in hESCs at 48 hours after transfection with a miRNA
knockdown control or miR-1305 knockdown (KD) and control
siRNA or POLR3G siRNA. The miRNA knockdown control was set
to 1.0 and all other values were calculated with respect to that.
Data is presented as mean6 SEM (n5 3). Significance was
assessed using Student t-test, *p< .05, **p< .01.
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epiblast development and which could be addressed using the
naive pluripotent stem cell model.
It is of interest to note that POLR3G modulation impact
hESCs in a more profound way than by modulating miR-1305
expression. One possible explanation for this is that POLR3G
inhibition and overexpression can be more easily achieved by
directly targeting POLR3G rather than its regulator, miR-1305.
Another possibility is that miR-1305 could be regulating other
targets in addition to POLR3G and which may play different
roles in pluripotency and differentiation. An example of this is
FOXA2 whose expression was downregulated upon miR-1305
overexpression and vice versa. FOXA2 is a hepatocyte nuclear
factor, shown to be important for transcriptional activation of
liver-specific genes [33]. Downregulation of miR-1305 at the
pluripotent stem cells did not result in overexpression of oth-
er endodermal markers other than FOXA2, suggesting that a
direct impact on differentiation to definitive endoderm
through a FOXA2-miR-1305 interaction is unlikely at this early
differentiation window. This could be due to the fact that sim-
ilarly to embryonic development, delineation of key germ
layers has not occurred as yet. However, it may be possible
that a FOXA2 overexpression mediated by miR-1305 downre-
gulation at the early stages of endodermal differentiation
could provide a necessary and important cue for directing dif-
ferentiation of human pluripotent stem cells to definitive
endodermal lineages. This merits further investigation togeth-
er with the possibility of miR-1305 binding to FOXA2 and reg-
ulating its expression.
Our study showed that miR-1305 overexpression increased
cells apoptosis while its knockdown reduced the population of
apoptotic cells; however POLR3G has been shown to have no
impact on pluripotent stem cell apoptosis [26], indicating that
miR-1305 is likely to regulate apoptosis through other targets.
Indeed, target prediction software identified miR-1305 binding
sites in genes involved in regulation of apoptosis such as
BCL2, MDM2, and MDM4. These results indicate that miR-
1305 might have potential functions in regulating apoptosis,
but not via POLR3G. In addition to miR-1305 involvement in
apoptosis, our studies showed indicated that overexpression
of miR-1305 speeds up the G1/S entry. This together with the
highest expression of this miRNA in S phase of the cell cycle
led us to speculate that overexpression of miR-1305 could be
important for the maintenance of pluripotency. This was how-
ever contradicted by our miR-1305 overexpression experi-
ments which resulted in induction of differentiation in
pluripotent stem cells and which suggest that miR-1305 role
in cell cycle regulation and maintenance of pluripotency could
be achieved by regulation of different target genes. The target
predictions software analysis identified CDK6, CYCLIND2 and
RUNX2 as potential targets of miR-1305, however only RUNX2
showed the expected downregulation upon miR-1305 overex-
pression and vice versa (data not shown), suggesting that the
latter could be an additional target of miR-1305. This possibili-
ty is further corroborated by a recent manuscript in which
RUNX2 was identified as one of the miR-1305 targets [34].
RUNX2 is an important osteogenic regulator shown to regu-
late the length of G1 phase of the cell cycle and apoptosis in
highly proliferating mammary epithelial cells [35, 36]. Given
that miR-1305 is also involved in cell cycle regulation and
apoptosis in pluripotent stem cells, it would be of interest to
further investigate whether these two processes are mediated
via regulation of RUNX2.
To date very little is known about the function of miR-
1305. Three previous studies have shown a high expression of
this miRNA in CpG island methylator-phenotype positive or
TP53-mutated colon tumours [37], human periodontal
ligament-derived stem cells derived from smokers [34] and a
lower expression in systemic lupus erythematosus and rheu-
matoid arthritis patient cells [38]. Our manuscript is the first
to describe a novel role for miR-1305 in regulation of
pluripotency-early differentiation balance, cell cycle regulation
and survival of pluripotent stem cells (Fig. 6). Whilst we have
provided solid evidence that miR-1305 in regulating pluripo-
tency is mediated by targeting another pluripotency factor,
POLR3G, further work is needed to understand how this sin-
gle miRNA is also able to affect pluripotent self-renewal, dif-
ferentiation and survival.
MATERIALS AND METHODS
Cell Culture
All hESCs and hiPSCs were cultured on Matrigel (growth-fac-
tor-reduced; BD Biosciences, NJ, USA) coated plates with
mTeSR1 media (Stem Cell Technologies) according to Wicell
Inc. protocols. Cells were passaged every 4–5 days at 80%
confluence by using 0.02% EDTA (Versene, Waltham, MA,
USA). All visible differentiated cells were manually removed
before further passaging.
Pluripotent Stem Cell Differentiation via the EB
Method
The hESCs were cultured on Matrigel coated plate with
mTeSR1 media. When 80%-90% confluence was observed, the
cells were digested by collagenase IV and resuspended in
human EB media, KO-DMEM (Thermo Fisher, Waltham, MA,
USA), 1% L-glutamine (Thermo Fisher, Waltham, MA, USA), 1%
nonessential amino acids (Thermo Fisher, Waltham, MA, USA),
20% Fetal Bovine Serum (Thermo Fisher, Waltham, MA, USA).
Three wells of hESCs colonies were transferred to one well of
the ultra-low attachment six-well plates (Corning, New York,
USA) for EB formation.
Figure 6. Schematic representation summarising the role of
miR-1305 in regulation of hESCs pluripotency-differentiation bal-
ance, cell survival and cell cycle. Arrows indicate stimulatory
modifications, blocked lines show inhibitory modifications and
dashed lines indicate regulation mechanism that are still unclear,
? indicates scientific questions that have not yet been solved.
Black lines represent data obtained from this manuscript, where-
as red lines indicate data obtained from published literature.
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Cell Cycle Synchronization
For cell cycle synchronization, the hESCs were collected, proc-
essed as previously described by Neganova et al. [20] and
Zhang et al. [21].
Cell Cycle Analysis
Cell cycle analysis was performed using Cycletest Plus DNA
Reagent Kit (BD, NJ, USA). hESCs were harvested by accutase
treatment and counted with a hemocytometer. 500,000 cells
were fixed, permeabilized, and stained in accordance with the
manufacturers’ instructions, and the sample was analyzed by
flow cytometry using a FACSCalibur measuring FL2 area versus
total counts. The data were analyzed using ModFit (Tree Star,
Inc., http://mycyte.org/) and FlowJo (Tree Star, Inc., http://
mycyte.org/) softwares to generate the percentages of cells in
G1, S, and G2 to M phases of the cell cycle.
Apoptosis Assay
Apoptosis was detected using the Annexin-V-FITC apoptosis
detection kit and 647 Mouse anti-Cleaved PARP (BD Bioscience,
NJ, USA). The protocol was performed in accordance with the
manufacturer’s instructions. The hESCs were collected processed
and analysed as previously described (Zhang et al. 2009) [21].
miRNA Expression Analysis
Agilent human miRNA (V3) 8X15K microarray were used for
miRNA analysis of each sample with three biological repli-
cates. Total RNA was extracted from unsynchronised and
synchronised hESCs using the mirVana miRNA Isolation Kit
(Ambion, Waltham, MA, USA) according to the manufacturer’s
instructions. RNA quality was assessed using the RNA 6000
Nano Kit on the 2100 Bioanalyzer instrument (Agilent Technol-
ogies, Santa Clara, CA, USA) according to the manufacturer’s
instructions.
RNA Extraction, Reverse Transcription and qRT-PCR
Total RNA isolation was performed using the ReliaPrep RNA
Cell Minprep System (Promega). RNA quality was evaluated
using the NanoDrop 2000 spectrophotometer (Thermo Fisher).
Total RNA was reverse-transcribed into cDNA using GoScript
Reverse Transcription System. qRT-PCR was performed using
the QuantStudio 7 Flex Real-Time PCR System (Life Technolo-
gies, Waltham, MA, USA), and the GoTaq qPCR Master
(Promega, Madison, WI, USA) according to the manufacturer’s
instructions. Primer sequences used for qRT-PCR are provided
in Supporting Information Table 4.
miRNA Reverse Transcription and qRT-PCR
TaqMan MicroRNA Reverse Transcription Kit was used for
miRNA reverse transcription. One microgram of total RNA
sample were used per miRNA RT reaction. TaqMan MicroRNA
probe (Thermo Fisher) was used as the miRNA Reverse Tran-
scription (RT) primer. qRT-PCR was performed using the
QuantStudio 7 Flex Real-Time PCR System (Thermo Fisher,
Waltham, MA, USA), and the TaqMan Small RNA Assays kit
(Thermo Fisher, Waltham, MA, USA) according to the manu-
facturer’s instructions.
Western Blotting
Protein (30 mg) from whole cell extracts was used for western
blotting analysis. Antibodies used for Western Blotting are as
follows: ZIC2 (1:1000, Abcam, Cambridge, MA, USA), LIN28A
(1:1000, Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA),
GAPDH (1:750, Abcam), POLR3G (1:500, Santa Cruz Biotech-
nology, Santa Cruz, CA, USA)
Small Interfering RNAs and miRNA Transient
Transfection
POLR3G siRNAs were obtained from Thermo Fisher (4390824).
The hESCs were transfected with si-control or si-POLR3G by
Lipofectamine RNAiMAX Transfection Reagent according to
the manufacturer’s instructions.miRNA mimics are small,
chemically modified double-stranded RNAs and miRNA inhibi-
tor are small, chemically modified single-stranded RNAs. The
hESCs and hiPSCs were transfected with 60 pmoles miRNA
mimic (Invitrogen Cat. #4464066) or inhibitor (Invitrogen Cat.
#4464084) by Lipofectamine RNAiMAX Transfection Reagent
according to the manufacturer’s instructions. In brief, the
hESCs and hiPSCs were first dissociated by incubating with
EDTA (0.02%). 3 3 105 cells were seeded into one well of a
12 well plate one day before lipofection. 6ll LipofectamineVR
RNAiMax reagent and 60 pmoles miRNA mimic or inhibitor
were used for transfection of one well.
Generation of a POLR3G Overexpressing Stable
Cell Line
The POLR3G full coding sequences was isolated from cDNA
generated from hESC line using the following oligonucleotides:
POLR3G Forward 50-GCG ATC GCA AVA TGG ATG AGG C-30 and
POLR3G Reverse 50- GCG GCC GCT TGT TTG TGG TGA TTG-30.
The full length fragment was ligated into the pCAG-IP vector.
hESCs were transfected with control empty Vector or POLR3G
construct by Lipofectamine 3000 (Invitrogen, Waltham, MA,
USA) following manufacturer’s instructions. 2 days after trans-
fection, stable clones were selected by using puromycin (1.0
mg/ml) for 7 days. The positive clones were expanded in
mTeSR1 with 0.5 mg/ml puromycin. The expression level of
POLR3G in stable cell lines was assessed by qRT-PCR and
western blotting.
Luciferase Assays
The cells were seeded at a density of 1 3 105 per well into
24-well plates 24 hours before transfection. To examine the
effect of miR-1305 on the POLR3G reporter, control vector or
POLR3G expression plasmids, miRNA overexpression control
or miR-1305 overexpression were co-transfected with the
reporter by Lipofectamine 3000 (Thermo Fisher, Waltham,
MA, USA) following manufacturer’s instructions. Cell extracts
were prepared 48 hours after transfection. Luciferase activities
were evaluated with a Dual-Luciferase Assay System
(Promega, Madison, WI, USA) according to the manufacturer’s
recommendations.
Statistical Analysis
Quantitative data are expressed as means6 SEM, n5 3. Sta-
tistical significance was determined by the Student’s t-test. p-
value <.05 was considered as statistically significant (*p <.05,
**p <.01).
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CONCLUSION
In summary, our results suggest that miR-1305 regulate plu-
ripotency, cell survival and cell cycle in human Pluripotent
Stem cells. Overexpression of miR-1305 induced differentia-
tion of pluripotent stem cells, increased cell apoptosis and
sped up G1/S transition, while its downregulation facilitated
the maintenance of pluripotency and increased cell survival.
miR-1305 regulate the balance between maintenance of plu-
ripotency and differentiation by targeting POLR3G. Overex-
pression of POLR3G rescued pluripotent stem cell
differentiation induced by miR-1305 overexpression. In con-
trast, knock-down of POLR3G expression abolished the miR-
1305-knockdown mediated enhancement of pluripotency,
thus validating its role as miR-1305 target in human pluripo-
tent stem cells.
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